Patents Represented by Attorney James Scott Elmer
-
Patent number: 6020153Abstract: The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.Type: GrantFiled: September 16, 1994Date of Patent: February 1, 2000Assignee: Ciba-Geigy CorporationInventors: Norman Hardman, Laura Lee Gill, Ronald F. J. de Winter, Kathrin Wagner, Christoph Heusser
-
Patent number: 6001846Abstract: A method for preparing 1,2-dihydroquinolines that is more flexible than the Skraup reaction is provided. The method comprises treating an ortho-alkenyl aniline with a ketone in the presence of a Lewis acid. Novel intermediates and products of this method useful as steroid receptor modulators, as well as pharmaceutical compositions and methods of use thereof are also claimed.Type: GrantFiled: February 17, 1998Date of Patent: December 14, 1999Assignee: Ligand Pharmaceuticals IncorporatedInventors: James P. Edwards, Todd K. Jones, Josef D. Riggenberg, Erick M. Carreira
-
Patent number: 5998654Abstract: Trienoic compounds having activity as antagonists for retinoic acid receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their therapeutic use.Type: GrantFiled: July 25, 1997Date of Patent: December 7, 1999Assignee: Ligand Pharmaceuticals IncorporatedInventors: Marcus F. Boehm, Lin Zhang
-
Patent number: 5922569Abstract: The invention concerns a method for the production of a polypeptide with the aid of genetically engineered yeast cells which contain not more than one functional CUP1 gene in the genome and carry a plasmid comprising a gene coding for said polypeptide and a functional CUP1 gene; and said yeast cells and said plasmids.Type: GrantFiled: May 26, 1995Date of Patent: July 13, 1999Assignee: Ciba-Geigy CorporationInventors: Jutta Heim, Thomas Hottiger, Gabriele Pohlig, Peter Furst
-
Patent number: 5843676Abstract: The invention relates to novel purified human immunoglobulin E binding factors (IgE-BFs), its individual optionally glycosylated proteins, and fragments thereof, processes for the purification of IgE-BFs, novel monoclonal antibodies to lymphocyte cellular receptors for IgE (Fc.sub..epsilon. R) crossreacting with IgE-BFs, derivatives thereof, processes for the preparation of these antibodies and their derivatives, hybridoma cell lines that produce these antibodies, processes for the preparation of said hybridoma cell lines, the use of the monoclonal antibodies and their derivatives for the qualitative and quantitative determination of IgE-BFs, test kits containing the monoclonal antibodies and/or their derivatives, the use of the monoclonal antibodies for the purification of IgE-BFs, the use of purified IgE-BFs, its individual optionally glycosylated proteins and/or fragments thereof for the prevention and/or treatment of allergy, and to pharmaceutical preparations containing them.Type: GrantFiled: May 16, 1996Date of Patent: December 1, 1998Assignee: Ciba-Geigy CorporationInventor: Guy Delespesse
-
Patent number: 5708148Abstract: A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.Type: GrantFiled: November 16, 1994Date of Patent: January 13, 1998Assignee: CIBA GEIGY CorporationInventors: Albert Schmitz, Walter Marki
-
Patent number: 5696130Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: June 5, 1995Date of Patent: December 9, 1997Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, David T. Winn, Mark E. Goldman, Lawrence G. Hamann, Lin Zhi, Luc J. Farmer, Robert L. Davis
-
Patent number: 5696133Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiting steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: June 5, 1995Date of Patent: December 9, 1997Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, Mark E. Goldman, Charlotte L.F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi, Lawrence G. Hamann, Luc J. Farmer, Robert L. Davis
-
Patent number: 5696127Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: June 5, 1995Date of Patent: December 9, 1997Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, Lin Zhi, James P. Edwards, Christopher M. Tegley, Sarah J. West
-
Patent number: 5693646Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: June 5, 1995Date of Patent: December 2, 1997Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, Christopher M. Tegley, Lin Zhi, James P. Edwards, Sarah J. West
-
Patent number: 5693647Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: June 5, 1995Date of Patent: December 2, 1997Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, Lin Zhi, Christopher M. Tegley, David T. Winn, Lawrence G. Hamann, James P. Edwards, Sarah J. West
-
Patent number: 5688810Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: June 5, 1995Date of Patent: November 18, 1997Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, Mark E. Goldman, Charlotte L.F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi
-
Patent number: 5688808Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: June 5, 1995Date of Patent: November 18, 1997Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, David T. Winn, Lin Zhi, Lawrence G. Hamann, Christopher M. Tegley, Charlotte L. F. Pooley
-
Patent number: 5646037Abstract: The invention relates to the field of genetic engineering and provides novel hybrid vectors based on the yeast two micron plasmid. The novel hybrid vectors are stably maintained in the cell during proliferation and are useful for the expression of heterologous genes in yeast in large scale batch and particularly in continuous culture.Type: GrantFiled: November 2, 1994Date of Patent: July 8, 1997Assignee: Ciba-Geigy CorporationInventor: Frank Buxton
-
Patent number: 5618690Abstract: The invention concerns novel DNA molecules encoding a modified, endoplasmic reticulum-located "dibasic processing endoprotease" and the use of said endoplasmic reticulum-located "dibasic processing endoprotease" for the correct processing of heterologous polypeptides in transformed hosts.Type: GrantFiled: June 5, 1995Date of Patent: April 8, 1997Assignee: CIBA-Geigy CorporationInventors: Bhabatosh Chaudhuri, Christine Stephan, Peter Seeboth, Howard Riezman
-
Patent number: 5610178Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydroxy, 2-hydroxyethoxy, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkanoyloxy, halogen, amino, azido, a keto, p-nitrobenzenesulfonyl or a pyranyloxy group of the formula ##STR2## wherein X is a group of the formula ##STR3## wherein R.sub.3 is hydroxy, C.sub.1 -C.sub.4 alkanoyloxy or organic sulfonyloxy, andR.sub.4 is hydroxy or carbamoyloxy,R.sub.2 is hydrogen, hydroperoxy, hydroxy or methoxy,Y is a group of the formula ##STR4## wherein R.sub.5 is hydroxy or C.sub.1 -C.sub.4 alkanoyloxy, andR.sub.6 and R.sub.7 each independently of the other is hydrogen or methyl, are suitable for the preparation of a medicament for the prophylaxis and treatment of diseases that respond to the inhibition of the osteoclast proton pump.Type: GrantFiled: August 9, 1994Date of Patent: March 11, 1997Assignee: Ciba-Geigy CorporationInventors: Axel Zeeck, Kai U. Bindseil, Claudia Boddien
-
Patent number: 5610042Abstract: The present invention is drawn to the production of fertile transformed wheat plants. The method involved subjecting wheat tissues to high velocity microprojectile bombardment, selecting for transformed cells, and regenerating stably transformed fertile plants from the transformed cells.Type: GrantFiled: November 1, 1993Date of Patent: March 11, 1997Assignee: Ciba-Geigy CorporationInventors: Yin-Fu Chang, James R. Wong, Andrea Itano, Stephen J. Mejza, Leslie Walker
-
Patent number: 5580559Abstract: Novel single-chain hybrid plasminogen activators having an amino acid sequence composed of at least two subsequences corresponding in amino acid identity and number to subsequences of human t-PA and of human u-PA, and mutants thereof in which at least one of the N-glycosylation sites is modified such that glycosylation cannot take place at these sites exhibit valuable pharmacological properties. The hybrid plasminogen activators are produced by recombinant DNA technology.Type: GrantFiled: September 23, 1994Date of Patent: December 3, 1996Assignee: Ciba-Geigy CorporationInventors: Bhanu Rajput, Bhabatosh Chaudhuri, Fredericus A. M. Asselbergs, Bernd Meyhack, Jutta Heim, Jan van Oostrum, Sefik Alkan
-
Patent number: 5571894Abstract: The invention concerns recombinant antibodies directed to the extracellular domain of the human growth factor receptor c-erbB-2 comprising a light chain variable domain and a heavy chain variable domain of a monoclonal antibody, monoclonal antibodies directed to c-erbB-2 themselves, a method of manufacturing those recombinant and monoclonal antibodies, hybridoma cells secreting those monoclonal antibodies, a method of manufacturing those hybridoma cells, DNAs encoding the heavy and light chain variable domains and the recombinant antibody, a method of manufacturing that DNA, hybrid vectors suitable for the expression of that DNA, host cells transformed with that DNA, and processes of using those recombinant and monoclonal antibodies in the diagnosis and treatment of tumors.Type: GrantFiled: April 29, 1994Date of Patent: November 5, 1996Assignee: Ciba-Geigy CorporationInventors: Winfried S. Wels, Nancy E. Hynes, Ina-Maria Harweth, Bernd Groner, Norman Hardman, Markus Zwickl
-
Patent number: 5563074Abstract: The present invention relates to monoclonal antibodies that are distinguished by a high degree of selectivity and affinity towards triasulfurone and that are therefore outstandingly suitable for use in an immunoassay for the rapid and effective detection of triasulfurone. The present invention relates also to hybridoma cell lines that produce the said monoclonal antibodies and to immunological methods for the detection of triasulfurone in soil, water or air samples using the said monoclonal antibodies and to test kits that may be used in those detection methods.Type: GrantFiled: July 15, 1994Date of Patent: October 8, 1996Assignee: Ciba-Geigy CorporationInventors: Jean-Marc Schlaeppi, Klaus Ramsteiner, Willy Meyer